A Proof-of-Concept for Safety Evaluation of Inhalation Exposure to Known Respiratory Irritants Using In Vitro and In Silico Methods

被引:0
|
作者
Sadekar, Nikaeta [1 ]
Behrsing, Holger Peter [2 ]
Hansen, Tanja [3 ]
Patel, Vivek [2 ]
Paulo, Hazel [4 ]
Rae, Alex [4 ]
Ritter, Detlef [3 ]
Schwarz, Katharina [3 ]
Api, Anne Marie [1 ]
机构
[1] Res Inst Fragrance Mat Inc, Mahwah, NJ 07430 USA
[2] Inst Vitro Sci Inc, Gaithersburg, MD 20878 USA
[3] Fraunhofer Inst Toxicol & Expt Med ITEM, D-30625 Hannover, Germany
[4] Charles River Labs Edinburgh Ltd, Elphinstone Res Ctr, Tranent EH33 2NE, England
关键词
in vitro; in silico; exposure assessment; safety assessment; inhalation; threshold of toxicological concern; CELL-LINE; HEALTH; MODEL; THRESHOLDS; PRODUCTS; RISK;
D O I
10.3390/toxics13010035
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
There is increased interest in developing non-animal test systems for inhalation exposure safety assessments. However, defined methodologies are absent for predicting local respiratory effects from inhalation exposure to irritants. The current study introduces a concept for applying in vitro and in silico methods for inhalation exposure safety assessment. Three in vitro systems, representing the upper (MucilAir (TM)-nasal epithelial tissue) and lower (A549 cells and human precision-cut lung slices) human respiratory regions, were exposed to six respiratory irritants. These irritant exposures were conducted as liquid droplets, aerosol, or vapors, and samples were collected over 24 h. Cytotoxicity, cytokine release, epithelial resistance, oxidative stress, and mitochondrial membrane potential were measured. To determine the human relevance of in vitro exposures, airway surface depositions were predicted by simulating airborne concentrations equivalent to the Cramer class III inhalation threshold of toxicological concern limit of 0.47 mg/person/day using an in silico model. A > 100-fold margin of exposure was calculated comparing lowest concentrations showing in vitro effects to in silico simulated values. While further studies are needed, this manuscript presents a basic requirement for employing non-animal methods to inform inhalation exposure safety assessments by combining in vitro and in silico assays.
引用
收藏
页数:23
相关论文
共 50 条
  • [41] Evaluation of the Pink Esthetic Score for Single Implants in the Esthetic Zone Using Intraoral Scanning Data: A Proof-of-Concept Study
    Wu, Ziang
    Su, Guanyu
    Yu, Xinbo
    Ye, Lijuan
    Wang, Feng
    Xu, Chun
    JOURNAL OF ESTHETIC AND RESTORATIVE DENTISTRY, 2025,
  • [42] Privacy-Preserving Methods for Feature Engineering Using Blockchain: Review, Evaluation, and Proof of Concept
    Jones, Michael
    Johnson, Matthew
    Shervey, Mark
    Dudley, Joel T.
    Zimmerman, Noah
    JOURNAL OF MEDICAL INTERNET RESEARCH, 2019, 21 (08)
  • [43] Innovative Visualization Approach for Biomechanical Time Series in Stroke Diagnosis Using Explainable Machine Learning Methods: A Proof-of-Concept Study
    Apostolidis, Kyriakos
    Kokkotis, Christos
    Karakasis, Evangelos
    Karampina, Evangeli
    Moustakidis, Serafeim
    Menychtas, Dimitrios
    Giarmatzis, Georgios
    Tsiptsios, Dimitrios
    Vadikolias, Konstantinos
    Aggelousis, Nikolaos
    INFORMATION, 2023, 14 (10)
  • [44] Early assessment of proarrhythmic risk of drugs using the in vitro data and single-cell-based in silico models: proof of concept
    Abbasi, Mitra
    Small, Ben G.
    Patel, Nikunjkumar
    Jamei, Masoud
    Polak, Sebastian
    TOXICOLOGY MECHANISMS AND METHODS, 2017, 27 (02) : 88 - 99
  • [45] Establishing short-term occupational exposure limits (STELs) for sensory irritants using predictive and in silico respiratory rate depression (RD50) models
    Russell, Anthony J.
    Vincent, Melissa
    Buerger, Amanda N.
    Dotson, Scott
    Lotter, Jason
    Maier, Andrew
    INHALATION TOXICOLOGY, 2024, 36 (01) : 13 - 25
  • [46] Using FDA-approved drugs as off-label fluorescent dyes for optical biopsies: from in silico design to ex vivo proof-of-concept
    Larson, Michael C.
    Gmitro, Arthur F.
    Utzinger, Urs
    Rouse, Andrew R.
    Woodhead, Gregory J.
    Carlson, Quinlan
    Hennemeyer, Charles T.
    Barton, Jennifer K.
    METHODS AND APPLICATIONS IN FLUORESCENCE, 2021, 9 (03):
  • [47] Phase IIa Proof-of-Concept Evaluation of the Antiviral Efficacy, Safety, Tolerability, and Pharmacokinetics of the Next-Generation Maturation Inhibitor GSK3640254
    Spinner, Christoph D.
    Felizarta, Franco
    Rizzardini, Giuliano
    Philibert, Patrick
    Mitha, Essack
    Domingo, Pere
    Stephan, Christoph J.
    DeGrosky, Michelle
    Bainbridge, Veronica
    Zhan, Joyce
    Dumitrescu, Teodora Pene
    Jeffrey, Jerry L.
    Xu, Jianfeng
    Halliday, Fiona
    Gan, Jianjun
    Johnson, Mark
    Gartland, Martin
    Joshi, Samit R.
    Lataillade, Max
    CLINICAL INFECTIOUS DISEASES, 2022, 75 (05) : 786 - 794
  • [48] Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept
    Leboeuf, C.
    Roser-Schilder, J.
    Lambotin, M.
    Durand, S.
    Wu, T.
    Fauvelle, C.
    Su, B.
    Bole-Richard, E.
    Deschamps, M.
    Ferrand, C.
    Tiberghien, P.
    Pessaux, P.
    Baumert, T. F.
    Robinet, E.
    GENE THERAPY, 2015, 22 (02) : 172 - 180
  • [49] Prevention of hepatitis C virus infection by adoptive allogeneic immunotherapy using suicide gene-modified lymphocytes: an in vitro proof-of-concept
    Leboeuf, Celine
    Roser-Schilder, Joelle
    Lambotin, Melanie
    Durand, Sarah
    Wu, Tao
    Deschamps, Marina
    Ferrand, Christophe
    Tiberghien, Pierre
    Pessaux, Patrick
    Baumert, Thomas F.
    Robinet, Eric
    HEPATOLOGY, 2014, 60 : 1170A - 1170A
  • [50] In vitro and in vivo proof-of-concept studies of extracellular protein degradation using novel M6PR-targeting chimeras (MTACs)
    Molz, Lisa
    Liu, Hu
    Zhu, Nanqun
    Karra, Srinivasa
    Tozzo, Effie
    JOURNAL OF IMMUNOLOGY, 2024, 212 (01):